AI assistant
Sending…
SOLESENCE, INC. — Director's Dealing 2025
Jan 13, 2025
33563_dirs_2025-01-13_9a249916-21fc-4f52-9647-f886427c7d42.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NANOPHASE TECHNOLOGIES Corp (NANX)
CIK: 0000883107
Period of Report: 2024-12-31
Reporting Person: Beres Laura M (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | Common Stock (Right to Buy) | $2.44 | A | 9000 | Acquired | 2031-12-31 | Common Stock (9000) | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Common Stock (right to purchase) | $0.62 | 2027-10-28 | Common Stock (10000) | 10000 | Direct |
| Common Stock (right to purchase) | $4.17 | 2028-12-28 | Common Stock (15000) | 15000 | Direct |
| Common Stock (right to purchase) | $1.165 | 2029-12-20 | Common Stock (15000) | 15000 | Direct |
| Common Stock (right to purchase) | $0.61 | 2030-12-27 | Common Stock (12600) | 12600 | Direct |
Footnotes
F1: Subject to certain restrictions, beginning on this date, options vest in three equal annual installments.
More from SOLESENCE, INC.
Interim / Quarterly Report
2026
May 12
Regulatory Filings
2026
May 12
Regulatory Filings
2026
Apr 29
Annual Report
2026
Apr 23
Annual Report
2026
Mar 31
Regulatory Filings
2026
Mar 31
Director's Dealing
2025
Dec 30
Director's Dealing
2025
Dec 11
Board/Management Information
2025
Dec 2
Board/Management Information
2025
Dec 1